A drug maker boosted the price of its opioid-overdose antidote by 600 percent, and taxpayers suffered

In order to capitalize on the opioid crisis, a small company that sells a version of naloxone, a decades-old drug that is widely used to reverse the effect of opioid and heroin overdoses, raised the price of its product by more than 600 percent between 2014 and 2017, which cost the federal government more than $142 million, according to a lengthy report from a Senate subcommittee.